...Hematology, Cardiovascular, Cancer Hired: Kenneth Bate as president and CEO, formerly president and CEO at NitroMed Inc....

...Nitromed Inc. unit unlicensed IP covering nitric oxide (NO)-donating compounds for € 2 million ($2.6 million). NitroMed...
...receive an additional € 4 million ($5.3 million) upon NicOx fulfilling certain future business criteria. NitroMed...
...which is marketed in the U.S. to treat heart failure in black patients. Deerfield acquired NitroMed...

...Cytokinetics Inc.'s cardiac myosin activator CK-1827452 has completed Phase IIa testing to treat heart failure. NitroMed Inc.'s...

...said portfolio manager Andy Smith. "By the time Genentech, CV Therapeutics, Tepnel Life Sciences and NitroMed...
...was acquired by Gen-Probe Inc. (NASDAQ:GPRO), CV Therapeutics Inc. was acquired by Gilead (NASDAQ:GILD), and NitroMed Inc....

...Two separate takeouts involving NitroMed (NASDAQ:NTMD) and Exact Sciences (NASDAQ:EXAS) were upset last week, and a...
...have their own ideas about what to do with the assets. Deerfield Management finally snatched NitroMed...
...a tie-up between the two cancer companies. Deer ponies up Deerfield, which owns 12% of NitroMed...

...in cash, valuing the biotech at $36.9 million. The price is a 25% premium to NitroMed's...
...of $0.64 on Jan. 26, before the deal was announced, and a 167% premium to NitroMed's...
...failure in black patients. Cowen and Co. LLC advised NitroMed. Archemix Corp. , Cambridge, Mass. NitroMed Inc....

...be acquired by Deerfield Management for $0.80 per share in cash. The price would value NitroMed...
...at $36.9 million based on 46.1 million shares outstanding and is a 25% premium to NitroMed's...
...of $1.5 million and $900,000 to Archemix and JHP, respectively. Cowen advised NitroMed. On Tuesday, NitroMed...

...to acquire NitroMed from $0.50 to $0.65 per share in cash. Subsequently, on Jan. 14, NitroMed...
...that Deerfield estimates will be at least $0.75 per share. A $0.75 offer would value NitroMed...
...$34.6 million based on 46.1 million shares outstanding and would be a 150% premium to NitroMed's...